| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/17/2003 | US6579696 Comprising diaminobutyric acid having a gamma amino group and amino acid selected from cysteine, alanine and lysine; use in prevention and treatment of sepsis |
| 06/17/2003 | US6579688 Stabilizing diluent for polypeptides and antigens |
| 06/17/2003 | US6579683 A ligand which is a member of Ephrin family of Eph family receptor interactive protein has been shown to be expressed by arterial endothelial cells but not by venous endothelial cell, useful for distinguishing target artieris and veins |
| 06/17/2003 | US6579533 Bioabsorbable drug delivery system for local treatment and prevention of infections |
| 06/17/2003 | US6579519 For therapy of eye infections such as conjunctivitis, blepharitis, keratitis sicca etc and to provide intraocular treatment through the cornea for diseases such as glaucoma or uveitis |
| 06/17/2003 | US6579517 Crosslinked, water soluble polyurethane; hair setting |
| 06/17/2003 | CA2251928C Antifungal compositions |
| 06/17/2003 | CA2118816C Composition for introducing nucleic acid complexes into higher eucaryotic cells |
| 06/17/2003 | CA2115504C Process for the stabilization of amphiphilic lipid(s)-containing vesicles and topical application composition containing said stabilized vesicles |
| 06/17/2003 | CA2094030C A method for drug formulation and a pharmaceutical composition |
| 06/17/2003 | CA2072249C Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane |
| 06/17/2003 | CA2046654C Radiolabeled proteins for diagnostic or therapeutic use |
| 06/12/2003 | WO2003048394A1 Polynucleotides and polypeptides associated with the development of osteoarthritis |
| 06/12/2003 | WO2003048306A2 Polycistronic expression of antibodies |
| 06/12/2003 | WO2003048207A2 Anti-dota antibody |
| 06/12/2003 | WO2003048201A1 Antimicrobial bolisin peptides |
| 06/12/2003 | WO2003048200A1 Nuclear protein 'shoca' - a component of the wnt signalling pathway |
| 06/12/2003 | WO2003048180A1 Crystalline form of a ribofuranosyluronamide derivative; a human adenosine a2a receptor agonist |
| 06/12/2003 | WO2003047650A2 Preparation of red blood cells having reduced immunogenicity |
| 06/12/2003 | WO2003047643A1 Controlled release therapeutic wound dressings |
| 06/12/2003 | WO2003047633A2 Treatment of angiogenesis disorders using targeted nanoparticles |
| 06/12/2003 | WO2003047632A1 Chimeric molecule for the treatment of th2-like cytokine mediated disorders |
| 06/12/2003 | WO2003047631A2 Clasp-pna-conjugate for the specific transport of nucleic acids which are thermally active |
| 06/12/2003 | WO2003047630A2 Method for oxygen treatment of unsaturated carbon compounds, novel epoxy-structured material obtained by the method, apparatus for carrying out the method and a therapeutic composition using the material |
| 06/12/2003 | WO2003047629A2 Treatment of diseases via the skin |
| 06/12/2003 | WO2003047620A2 Compositions and methods for producing vascular occlusion |
| 06/12/2003 | WO2003047609A1 A topical anti-itch formulation and a process for the preparation thereof |
| 06/12/2003 | WO2003047597A1 Combination of crystalline form of a ribofuranosyluronamide derivative and tiotropium salt |
| 06/12/2003 | WO2003047595A1 Pharmaceutical compositions comprising active vitamin d compounds |
| 06/12/2003 | WO2003047590A1 Antibiotic formulation and a method of making this formulation |
| 06/12/2003 | WO2003047589A1 Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission |
| 06/12/2003 | WO2003047587A1 Platinum derivative pharmaceutical formulations |
| 06/12/2003 | WO2003047580A1 Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess therewith |
| 06/12/2003 | WO2003047567A1 STABLE, ACID, AQUEOUS SOLUTION CONTAINING α-LIPONIC ACID (DERIVATIVES), METHOD FOR THE PRODUCTION THEREOF AND USE OF THE SAME |
| 06/12/2003 | WO2003047555A1 Transdermal therapeutic systems containing steroid hormones and propylene glycol monocaprylate |
| 06/12/2003 | WO2003047554A1 Transdermal drug delivery system of strychnine, brucine, securinine and their salts |
| 06/12/2003 | WO2003047552A2 Pharmaceutical composition comprising a 5ht1 receptor agonist |
| 06/12/2003 | WO2003047549A2 Post-coated liposome/lipoplex for targeted drug/gene delivery and lipid linked to a delivery, targeting or stabilising moiety |
| 06/12/2003 | WO2003047548A1 Pharmaceutical compositions in the form of gel or solution based on dihydrotestosterone, preparation method and uses thereof |
| 06/12/2003 | WO2003047537A1 Antimicrobial composition comprising soy oil, rice bran oil and jojoba oil |
| 06/12/2003 | WO2003047532A2 Compositions and methods for the therapeutic use of an atonal-associated sequence for a gastrointestinal condition |
| 06/12/2003 | WO2003047521A2 Composition and method for treatment of otitis media |
| 06/12/2003 | WO2003047519A2 'compressed annular tablet with molded triturate tablet for oral and intraoral' |
| 06/12/2003 | WO2003047518A2 Cyclodextrin grafted biocompatible amphiphilic polymer and methods of preparation and use thereof |
| 06/12/2003 | WO2003047511A2 Use of gingko biloba extracts to promote neuroprotection and reduce weight loss |
| 06/12/2003 | WO2003047502A1 Taste masked aqueous liquid pharmaceutical composition |
| 06/12/2003 | WO2003047499A2 Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting |
| 06/12/2003 | WO2003047494A2 Reverse micelle compositions and uses thereof |
| 06/12/2003 | WO2003047493A2 Stabilized reverse micelle compositions and uses thereof |
| 06/12/2003 | WO2003047367A1 Solid and stable creatine/citric acid composition(s) and compositions containing carbohydrate(s) or hydrates thereof, method for the production and use thereof |
| 06/12/2003 | WO2002000844A3 Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use |
| 06/12/2003 | WO2001073133A9 Compositions and methods for identifying and targeting cancer cells |
| 06/12/2003 | US20030109819 Adhesive preparations |
| 06/12/2003 | US20030109813 Energy-activated targeted cancer therapy |
| 06/12/2003 | US20030109699 Biopolymers; gene therapy, medical diagnosis |
| 06/12/2003 | US20030109684 Antitumor agents; transforming growth factor |
| 06/12/2003 | US20030109682 Maytansines and maytansine conjugates |
| 06/12/2003 | US20030109671 Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| 06/12/2003 | US20030109647 Biodegradable polyhydric alcohol esters |
| 06/12/2003 | US20030109587 Gelling composition |
| 06/12/2003 | US20030109575 Emulsion of tocopherol incorporating a co-solvent and, stabilized by biocompatible surfactants, as a vehicle or carrier for therapeutic drugs, which is substantially ethanol free and which can be administered to animals or humans by |
| 06/12/2003 | US20030109515 Pharmaceutical formulation of a platinum derivative |
| 06/12/2003 | US20030109514 Platinum derivative pharmaceutical formulations |
| 06/12/2003 | US20030109507 Relates to semisolid transcutaneous medicaments based on at least one oxidation-sensitive progestin or a pharmaceutically acceptable derivative thereof. The medicaments comprise ascorbic acid, an ascorbic acid derivative or a salt thereof |
| 06/12/2003 | US20030109496 Use of polysiloxanes containing at least one quaternary ammonium group as formulation auxiliary in formulations of larvicidal and/or ovicidal active compounds and to compositions containing active materials and carriers |
| 06/12/2003 | US20030109495 Topical treatment for diseases of joints and soft tissues with a proven scientific basis. The carrying agent is DMSO or (dimethyl sulfoxide) in purified form. they are antiinflammatory agents for joints and soft tissues |
| 06/12/2003 | US20030109494 Composition comprising ascorbic acid with dextran. Pharmaceutical composition for the treatment or prophylaxis of a condition in warm-blooded animals that responds to inhibition of oxygen free radicals, that comprises an amount |
| 06/12/2003 | US20030109492 Methods for enhancing the aqueous solubility of an active ingredient which is insoluble or sparingly soluble in water. In one preferred embodiment, solubilization of the active ingredient is enhanced by combining it with beta |
| 06/12/2003 | US20030109479 Bioactive substances useful for the delivery of effector units in animals. Also disclosed are methods for utilizing the bioactive substances of the invention. |
| 06/12/2003 | US20030109478 Nucleic acid formulations for gene delivery and methods of use |
| 06/12/2003 | US20030109475 Introducing a gene capable of modulating the genotype and phenotype into two or more tissues following systemic administration. The gene can be introduced into a mammalian host by way of an expression vector either as naked DNA or |
| 06/12/2003 | US20030109460 A pharmaceutical preparation which ensures stability and solubility of a hexacyclic camptothecin derivative prepared by adding a ring having a water-soluble group to camptothecin, wherein a pH-adjusting substance and, a sugar or sugar alcohol |
| 06/12/2003 | US20030109454 Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof |
| 06/12/2003 | US20030109442 Apolipoprotein A-I (ApoA-I), preferably a variant form such as Apolipoprotein A-I Milano (ApoA-IM), alone or more preferably in combination with a lipid carrier such as phospholipids or other drug, can be administered locally |
| 06/12/2003 | US20030109437 Peptides and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using proteins (and peptides derived from the amino acid sequences of such |
| 06/12/2003 | US20030109432 Anticancer polypeptide-metal complexes and compositions, methods of making, and methods of using same |
| 06/12/2003 | US20030109429 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 06/12/2003 | US20030109422 Process for the preparation of pharmaceutical formulations containing lactoferrin |
| 06/12/2003 | US20030109006 Isolation of lymphocytes, binding, forming culture product, cloning |
| 06/12/2003 | US20030108966 Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof |
| 06/12/2003 | US20030108705 Rigid polyvinyl alcohol encases fabric care, dishwashing, water- softening, laundry, rinse aid, antibacterial or refill compositions for a trigger type spray |
| 06/12/2003 | US20030108615 Also comprising a binder, a taste masking layer, a lubricant, and a binder/dissolution enhancer; storage stability; discoloration inhibition; materials handling; easy dosage adjustment |
| 06/12/2003 | US20030108611 Bioactive particulates having a cationic surfactant adsorbed on their surfaces to provide superior adhesion to a biological substrate, e.g., an insect, teeth, bone, nails, chitin, feathers, plants, mucous, skin; drug delivery |
| 06/12/2003 | US20030108610 An aqueous sol for localized drug delivery including a modifier polymer which gels at body temperature; the release rate of the drug is altered and controlled by increasing or decreasing polymer concentration; surgical adhesions |
| 06/12/2003 | US20030108609 Capable of suspending beneficial agents and homogeneously dispensing them over an extended period of time at body temperature and at low flow rates; storage stability; injections; grafting; proteinaceous drugs; antiagglomerants |
| 06/12/2003 | US20030108607 Film forming compositions containing sucralose |
| 06/12/2003 | US20030108603 Mixture of protein, hydrophilic polymer, group 1a alkyl sulfate and sugar |
| 06/12/2003 | US20030108602 Controlling releasing |
| 06/12/2003 | US20030108601 Liquid pharmaceutical for oral delivery |
| 06/12/2003 | US20030108600 Ubidecarenone compositions and capsules containing the same |
| 06/12/2003 | US20030108599 Surface treating with nonionic surfactant coating |
| 06/12/2003 | US20030108596 Lipophilic drug compositions |
| 06/12/2003 | US20030108595 Prevent deposits of amyloid; using sulfonate or sulfate compound |
| 06/12/2003 | US20030108588 Reduce restenosis coating on medical device |
| 06/12/2003 | US20030108586 Using gonadotropin releasing hormone antagonist |
| 06/12/2003 | US20030108575 Stabilized oral suspension formulation |
| 06/12/2003 | US20030108565 Sustained releas of protein using polymer and hydrophobic ion binding; inducing immunology response; autoimmune disease, anticancer agent |
| 06/12/2003 | US20030108556 Using polymer containing dextran or ethylene glycol units |
| 06/12/2003 | US20030108525 Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith |
| 06/12/2003 | US20030108511 Biocompatible, crosslinked polymer; surgical gel |